1
TITLE: Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228)  Full Text
AUTHORS: Francis Levi; Abdoulaye Karaboue; Raphael Saffroy; Christophe Desterke; Valerie Boige; Denis Smith; Mohamed Hebbar; Pasquale Innominato; Julien Taieb; Carlos Carvalho; Rosine Guimbaud; Christian Focan; Mohamed Bouchahda; Rene Adam; Michel Ducreux; Gerard Milano; Antoinette Lemoine;
PUBLISHED: 2017, SOURCE: BRITISH JOURNAL OF CANCER, VOLUME: 117, ISSUE: 7
INDEXED IN: WOS
2
TITLE: Four-year survival in patients (pts) undergoing liver surgery after neoadjuvant triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) for previously treated and unresectable liver metastases from kras wt colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228).
AUTHORS: Francis Levi; Michel Ducreux; Denis Michel Smith; Mohamed Hebbar; Celine Lepere; Focan, CNJ; Rosine Guimbaud; Pasquale F Innominato; Carlos Carvalho; Salvatore Tumolo; Stephanie Truant; Denis Castaing; Abdoulaye Karaboue; Valerie Boige; Mohamed Bouchahda; Philippe Rougier; Rene Adam;
PUBLISHED: 2014, SOURCE: 50th Annual Meeting of the American-Society-of-Clinical-Oncology in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 32, ISSUE: 15
INDEXED IN: WOS
3
TITLE: Constitutive single nucleotide polymorphisms (SNP) assessment for predicting tolerability and efficacy of triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) in patients (pts) with liver metastases from colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228).
AUTHORS: Francis Levi; Abdoulaye Karaboue; Raphael Saffroy; Elodie Peyric; Michel Ducreux; Denis Michel Smith; Mohamed Hebbar; Pasquale F Innominato; Simon Pernot; Carlos Carvalho; Rosine Guimbaud; Focan, CNJ; Mohamed Bouchahda; Rene Adam; Marie Christine Etienne Grimaldi; Gerard A Milano; Antoinette Lemoine;
PUBLISHED: 2014, SOURCE: 50th Annual Meeting of the American-Society-of-Clinical-Oncology in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 32, ISSUE: 15
INDEXED IN: WOS
4
TITLE: Final results of first European phase II trial of intravenous cetuximab (Cet) and hepatic artery infusion of irinotecan, 5-fluorouracil, and oxaliplatin in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after systemic treatment failure (OPTILIV, NCT00852228).
AUTHORS: Francis Levi; Valerie Boige; Mohamed Hebbar; Denis Smith; Celine Lepere; Focan, CNJ; Rosine Guimbaud; Carlos Carvalho; Salvatore Tumolo; Pasquale F Innominato; Yves Ajavon; Stephanie Truant; Denis Castaing; Thierry De Baere; Francis Kunstlinger; Abdoulaye Karaboue; Mohamed Bouchahda; Philippe R Rougier; Rene Adam; Michel Ducreux;
PUBLISHED: 2013, SOURCE: Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO) in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 31, ISSUE: 4
INDEXED IN: WOS
5
TITLE: Prediction of Survival by Neutropenia According To Delivery Schedule of Oxaliplatin-5-Fluorouracil-Leucovorin for Metastatic Colorectal Cancer in a Randomized International Trial (EORTC 05963)  Full Text
AUTHORS: Pasquale F Innominato; Sylvie Giacchetti; Thierry Moreau; Rune Smaaland; Christian Focan; Georg A Bjarnason; Carlo Garufi; Stefano Iacobelli; Marco Tampellini; Salvatore Tumolo; Carlos Carvalho; Abdoulaye Karaboue; Francis Levi;
PUBLISHED: 2011, SOURCE: CHRONOBIOLOGY INTERNATIONAL, VOLUME: 28, ISSUE: 7
INDEXED IN: Scopus WOS CrossRef